$Evaluating the antifracture efficacy of bisphosphonates.$

Evaluating the antifracture efficacy of bisphosphonates.

Oral bisphosphonate dosing schedules have evolved from the original daily regimens to weekly (alendronate and risedronate) and monthly (risedronate and ibandronate) regimens. Intravenous (i.v.) bisphosphonates are administered less frequently-quarterly ibandronate injection and yearly zoledronic aci...

Descripció completa

Dades bibliogràfiques
Autors principals:	Pazianas, M, Epstein, S, Zaidi, M
Format:	Journal article
Idioma:	English
Publicat:	2009

Ítems similars

Antifracture agents for prostate cancer patients on androgen deprivation therapy
per: Bhupendra P Singh, et al.
Publicat: (2010-01-01)

The sequential antifracturative treatment: a meta-analysis of randomized clinical trials
per: Angelo Fassio, et al.
Publicat: (2024-04-01)

Safety of bisphosphonates.
per: Pazianas, M, et al.
Publicat: (2011)

Bisphosphonates and bone quality.
per: Pazianas, M, et al.
Publicat: (2014)

Atrial fibrillation and bisphosphonate therapy.
per: Pazianas, M, et al.
Publicat: (2010)

Potential therapeutic effects of oral bisphosphonates on the intestine.
per: Pazianas, M, et al.
Publicat: (2011)

Safety issues with bisphosphonate therapy for osteoporosis.
per: Suresh, E, et al.
Publicat: (2014)

Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
per: Pazianas, M
Publicat: (2013)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
per: Alexander J Rodríguez, et al.
Publicat: (2022-06-01)

Cardiovascular Safety of Antifracture Medications in Patients With Osteoporosis: A Narrative Review of Evidence From Randomized Studies
per: Alexander J Rodríguez, et al.
Publicat: (2021-07-01)

Bisphosphonates and colon cancer: reply.
per: Pazianas, M, et al.
Publicat: (2013)

Bisphosphonates and colon cancer: Reply
per: Pazianas, M, et al.
Publicat: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates.
per: Pazianas, M, et al.
Publicat: (2013)

Eliminating the need for fasting with oral administration of bisphosphonates
per: Pazianas M, et al.
Publicat: (2013-10-01)

NE‐58025: A bisphosphonate with a low hydroxyapatite binding affinity
per: Michael Pazianas
Publicat: (2021-08-01)

Atrial fibrillation and the use of oral bisphosphonates.
per: Pazianas, M, et al.
Publicat: (2011)

Atrial fibrillation and the use of oral bisphosphonates
per: Michael Pazianas, et al.
Publicat: (2011-03-01)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
per: Pazianas, M, et al.
Publicat: (2010)

Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted.
per: Abrahamsen, B, et al.
Publicat: (2013)

NO ASSOCIATION BETWEEN THE USE OF ORAL BISPHOSPHONATES AND INCIDENCE OF ATRIAL FIBRILLATION
per: Pazianas, M, et al.
Publicat: (2010)

Comment on Tadrous et al.: comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.
per: Pazianas, M, et al.
Publicat: (2014)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
per: Pazianas, M, et al.
Publicat: (2008)

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker: Reply to Yarom and Elad
per: Pazianas, M, et al.
Publicat: (2008)

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
per: Pazianas, M, et al.
Publicat: (2007)

Impact of bisphosphonates in age-related macular degeneration: Retrospective cohort and nested case-control study
per: Garriga, C, et al.
Publicat: (2018)

Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study.
per: Pazianas, M, et al.
Publicat: (2012)

Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
per: Pazianas, M, et al.
Publicat: (2013)

Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
per: Garriga, C, et al.
Publicat: (2018)

Impact of bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study
per: Garriga, C, et al.
Publicat: (2018)

Bisphosphonates and Age-Related Macular Degeneration: A Propensity-Matched Cohort and Nested Case-Control Analysis
per: Garriga, C, et al.
Publicat: (2017)

Bisphosphonates
per: Bishop, N, et al.
Publicat: (2013)

Bisphosphonates
per: Fırat Öztürk
Publicat: (2009-04-01)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
per: Russell, R, et al.
Publicat: (2007)

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
per: Russell, R, et al.
Publicat: (2007)

Safety and efficacy of bisphosphonates in thalassemia patients with osteopenia/osteoporosis
per: Sujata Sharma, et al.
Publicat: (2023-04-01)

Efficacy of Bisphosphonates for the Treatment of Osteoporosis in Patients with Multiple Sclerosis
per: İlke Coşkun Benlidayı, et al.
Publicat: (2015-08-01)

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
per: Russell, R, et al.
Publicat: (2008)

Bisphosphonates: An update
per: Nalliappan Ganapathy, et al.
Publicat: (2012-01-01)

Bisphosphonates 2006
per: Russell, R
Publicat: (2006)

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
per: Pazianas, M, et al.
Publicat: (2012)